Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Target Identification in Anti-Tuberculosis Drug Discovery
Rita Capela, Rita Félix, Marta Clariano, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10482-10482
Open Access | Times Cited: 17

Showing 17 citing articles:

In silico elucidation and network pharmacology analysis of phytochemicals from Elephantorrhiza elephantina and Pentanisia prunelloides for antitubercular activity
Alaiha Zaheen, Pinki Francina Lefalo, Sanchaita Rajkhowa, et al.
Gene Reports (2025), pp. 102155-102155
Closed Access
Computational approaches: atom-based 3D-QSAR, molecular docking, ADME-Tox, MD simulation and DFT to find novel multi-targeted anti-tubercular agents
Debadash Panigrahi, Susanta Kumar Sahu
BMC Chemistry (2025) Vol. 19, Iss. 1
Open Access
Molecular docking, free energy calculations, ADMETox studies, DFT analysis, and dynamic simulations highlighting a chromene glycoside as a potential inhibitor of PknG in Mycobacterium tuberculosis
Muharib Alruwaili, Tilal Elsaman, Magdi Awadalla Mohamed, et al.
Frontiers in Chemistry (2025) Vol. 13
Open Access
Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis Therapy
Giulia Cazzaniga, Matteo Mori, Anna Griego, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Role of guanylate-binding protein 5 in inflammatory diseases, immune diseases, cancers, and its potential therapeutic implications
Xufan Sun, Guiyuan Jin, Huihui Zhou, et al.
Inflammopharmacology (2025)
Closed Access
Design, synthesis and biological evaluation of novel pyrido-[2,3-d]-pyrimidin-2-amine analogues as antimycobacterial agents
Boddupalli Venkata Siva Kumar, Yogesh Mahadu Khetmalis, Kosana Sai Chaitanya, et al.
Journal of Molecular Structure (2024) Vol. 1303, pp. 137600-137600
Closed Access | Times Cited: 4
Drug repurposing for bacterial infections
Mahnoor Ilyas, Muhammad Saad Latif, Alvina Gul, et al.
Progress in molecular biology and translational science (2024), pp. 1-21
Closed Access | Times Cited: 2
The progress of Mycobacterium tuberculosis drug targets
Xin Zhang, R Zhao, Yao Qi, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Artificial intelligence in drug discovery: A new frontier in the fight against Mycobacterium tuberculosis
Mohammad Abavisani, Alireza Khoshrou, Amirhossein Sahebkar
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103909-103909
Closed Access | Times Cited: 1
Computational approaches: Atom-based 3D-QSAR, molecular docking, ADME-Tox, MD simulation and DFT to find novel multi-targeted Anti-tubercular agents
Debadash Panigrahi, Susanta Kumar Sahu
Research Square (Research Square) (2024)
Open Access
Research Progress on the Drug Resistance Mechanism of <i>Mycobacterium </i><i>tuberculosis</i>
佳琦 庞
Advances in Clinical Medicine (2024) Vol. 14, Iss. 07, pp. 112-119
Closed Access
The Repurposing of FDA-Approved Drugs as FtsZ Inhibitors against Mycobacterium tuberculosis: An In Silico and In Vitro Study
Andrea Michel Tovar-Nieto, Luis Enrique Flores-Padilla, Bruno Rivas‐Santiago, et al.
Microorganisms (2024) Vol. 12, Iss. 8, pp. 1505-1505
Open Access
Enhance the Antimycobacterial Activity of Streptomycin with Ebselen as an Antibiotic Adjuvant Through Disrupting Redox Homeostasis
Chuanjiang Dong, Yueqing Wang, Yi Cai, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 3811-3824
Open Access
Challenging the Biginelli scaffold to surpass the first line antitubercular drugs: Mycobacterium tuberculosis thymidine monophosphate kinase (TMPK mt ) inhibition activity and molecular modelling studies
Mai S. El-Shoukrofy, A. I. Atta, Salwa M. Fahmy, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2024) Vol. 39, Iss. 1
Open Access
Exploring the factors influencing the ketoenamine-enolimine tautomeric equilibrium of pyridoxal 5′-phosphate in branched-chain aminotransferases
Xue Li, He Yu, Jiaqi Sun, et al.
Molecular Catalysis (2024) Vol. 569, pp. 114581-114581
Closed Access
Validation of DXS as an attractive drug target in mycobacteria
T Maila, M Nicolaai, Rendani Mbau, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Advancements and Challenges in Tuberculosis Drug Discovery: A Comprehensive Overview
Puja Kumari Agnivesh, Arnab Roy, Shashikanta Sau, et al.
Microbial Pathogenesis (2024) Vol. 198, pp. 107074-107074
Closed Access
1,3-Proton Transfer of Pyridoxal 5′-Phosphate Schiff Base in the Branched-Chain Aminotransferase: Concerted or Stepwise Mechanism?
Xue Li, Xiaoli Sun
The Journal of Physical Chemistry B (2023)
Closed Access | Times Cited: 1
Page 1

Scroll to top